Merck’s commitment to continue its presence in Iran

Author:
Actoverco
Date:
21 April 2019
11

Paolo Carly’s speech, General Manager of German Merck Company in the Middle East and North Africa at the inauguration of the new Actoverco Solid Drug Production Plant (Actoverco 2)

Paolo Carly’s speech, General Manager of German Merck Company in the Middle East and North Africa at the inauguration of the new Actoverco Solid Drug Production Plant (Actoverco 2):

According to Actoverco’s Public Relations, Paolo Carly said: “We are committed to not stop our activities in Iran.”

We also request from the Iranian Ministry of Health to be consistent in its policies. We are just at the beginning of cooperation with Actoverco, and the level of cooperation between Merck and Actoverco will increase in the fields of chemical and biotech drugs.

Reference: PHANA

Related Posts

4R4A5641-1-2048x1365

Actover Pharmaceutical Group Participates in the 10th IRAN PHARMA Exhibition

4R4A3136-2048x1365 (1)

Actoverco Medical Director Stated: A Strong Commitment to the “Pharmacovigilance” System Ensures the Safety and Reliability of Actover Products

M_HA18361-2048x1365

Actover Group Unveils “Zeponim” for the Management of Multiple Sclerosis and Ulcerative Colitis

nexus23

Nexus CEO Calls for Equal Market Opportunities for Domestic Supplements at Iran Supplex 2025

4R4A0525

Actover Pharmaceutical Group Showcases Its Neurology Portfolio at the 32nd Iranian Congress of Neurology and Clinical Electrophysiology